VIENNA — Only 7%-20% of people with chronic kidney disease (CKD) in the US are aware of their condition; meanwhile, the disease is projected to become […]

VIENNA — Spironolactone, a mineralocorticoid receptor antagonist (MRA), does not reduce the rates of cardiovascular (CV) death or heart failure in patients undergoing maintenance dialysis, according […]

Pegcetacoplan, a targeted C3/C3b inhibitor, shows sustained, robust effects on key markers of kidney disease in patients with C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis […]

VIENNA — The use of expanded-criteria donors for kidney transplantation in older and high-risk recipients did not provide the same survival benefit as the use of […]

VIENNA — Sibeprenlimab, a novel selective immune antibody, reduced the urine protein-to-creatinine ratio (uPCR) by more than half in patients with immunoglobulin A (IgA) nephropathy, according […]

Cardiovascular benefits associated with the SGLT2 inhibitor drug canagliflozin appear to be dose-dependent, with benefits in some key clinical endpoints — including mortality — observed only […]

VIENNA — Combining the SGLT2 inhibitor empagliflozin with finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), markedly and durably reduced albuminuria in patients with both chronic kidney […]